National Bank of Canada
CYTK icon

National Bank of Canada’s Cytokinetics CYTK Stock Holding History

National Bank of Canada’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3K Buy
248
+9
+4% +$572 ﹤0.01% 2221
2025
Q4 		$15.2K Buy
+239
New +$14.9K ﹤0.01% 2217
2024
Q1 		– Sell
-150
Closed -$12.6K – 2770
2023
Q4 		$12.6K Buy
+150
New +$5.43K ﹤0.01% 2115

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

National Bank of Canada's CYTK Position: Q1 2026 in Review

National Bank of Canada increased its Cytokinetics (CYTK) stake by 3.8% in Q1 2026, buying an estimated $572 and bringing the position to 248 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

National Bank of Canada first reported a position in CYTK in Q4 2023 and has held it in 3 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • National Bank of Canada held 248 shares of Cytokinetics worth $16.3K as of Q1 2026.
  • National Bank of Canada bought 9 Cytokinetics shares in Q1 2026, an estimated $572.
  • Cytokinetics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2221 holding.
  • National Bank of Canada first reported a position in Cytokinetics in Q4 2023 and has held it in 3 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.